The current share price indicates that stock is -4.74% away from its one year high and is moving 132.65% ahead of its 52-week low.

Several other hedge funds and other institutional investors have also bought and sold shares of FOLD.

05/24/2017 - Amicus Therapeutics, Inc. had its " rating reiterated by analysts at Bank of America Merrill Lynch. (NASDAQ:FOLD)'s near-term growth potential. The stock notched a 12-month high of $12.92 while $18.00 target is by far the most aggressive out of analysts who are now evaluating the company, $5.08 higher than the next highest 52-week price estimate.

During last 5 trades the stock sticks nearly 5.14%. BidaskClub raised shares of Amicus Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 24th. Closely-held shares are those owned by insiders, major shareholders and employees, while restricted stock refers to insider shares that can not be traded because of a temporary restriction such as the lock-up period after an initial public offering. (FOLD)'s latest closing price distance was at 45.56% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at 23.28% and 9.19% compared with the 20 Day Moving Average.

The current market capitalization of Amicus Therapeutics (NASDAQ:FOLD) stands at 1.47 Billion.

Based on their most recently released notes to investors, 3 analysts have a rating of "buy", 3 analysts "outperform", 0 analysts "hold", 0 analysts "underperform" and 0 analysts "sell". Before the market open, the tiny biotech announced that the US Food and Drug Administration (FDA) has cleared the way for the company to submit a New Drug Application (NDA) for its Fabry disease drug. On an average trading day, only about 2.6 million shares of Amicus change hands. Perceptive Advisors LLC acquired a new position in Amicus Therapeutics during the fourth quarter valued at about $85,964,000. Brown Advisory Inc. boosted its position in Amicus Therapeutics by 1.0% in the fourth quarter. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. However a year ago for the same quarter the company has reported $-1.17 EPS. The firm had revenue of $4.20 million for the quarter, compared to analyst estimates of $4.16 million. Chardan Capital Markets analysts stated on 12/04/2016 that they maintained their Buy rating. Leerink Swann reaffirmed an outperform rating and issued a $15.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, March 30th. The company's revenue was up 50.0% on a year-over-year basis. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of U.S. and worldwide trademark & copyright legislation. Amicus Therapeutics, Inc. has far performed well this year, with the share price up 106.44% since January. The correct version of this news story can be accessed at Relative volume is ratio between current volume and 3-month average value, intraday adjusted.

The Company also provided an update on the European launch of Galafold that as of June 30, 2017, there were 151 patients on reimbursed Galafold. Following the sale, the insider now owns 474,438 shares in the company, valued at approximately $3,795,504. The sale was disclosed in a filing with the SEC, which is available at the SEC website. These shares are worth $300,000 and were traded at $10 each. The disclosure for this sale can be found here.

The company has a one year high of $13.28 and a one year low of $4.41. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease.